Phathom Pharmaceuticals to Participate in November Investor Conferences
Phathom Pharmaceuticals (Nasdaq: PHAT) management is scheduled to participate in three investor conferences in November, beginning November 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Phathom Pharmaceuticals (Nasdaq: PHAT) management is scheduled to participate in three investor conferences in November, beginning November 10, 2026.
Fireside chats are scheduled at Guggenheim in Boston on November 10 at 3:00 p.m. EST; Stifel in New York on November 11 at 8:40 a.m. EST; and Jefferies in London on November 18 at 10:30 a.m. EST / 3:30 p.m. GMT. Management will also participate in one-on-one meetings at each conference.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences:
Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA
Date: Tuesday, November 10, 2026
Fireside Chat: 3:00 p.m. EST
Management to participate in one-on-one meetings throughout the conference
Stifel 2026 Healthcare Conference in New York, NY
Date: Wednesday, November 11, 2026
Fireside Chat: 8:40 a.m. EST
Management to participate in one-on-one meetings throughout the conference
Jefferies Global Healthcare Conference in London, UK
Date: Wednesday, November 18, 2026
Fireside Chat: 10:30 a.m. EST / 3:30 p.m. GMT
Management to participate in one-on-one meetings throughout the conference
To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for 90 days following the conclusion of each meeting.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the commercialization and development of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
